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1. Introduction 
The many studies on the immune mechanisms contributing to xenograft rejection have 
identified two types of antibodies (Abs) that form barriers to transplantation of xenografts 
into humans: 1. Natural and induced anti-Gal Abs, and 2. Induced anti-non gal Abs. The 
formidable barrier of anti-Gal Abs seems to have been removed by the generation of 
1,3galactosyltransferase (1,3GT) knockout (KO) pigs. However, the second immune 
barrier of anti-non gal Abs may be even more formidable than that of anti-Gal Abs. The anti-
non gal Ab barrier was not fully appreciated in the 1990’s when much of the research was 
focused on overcoming the first barrier of anti-Gal mediated hyperacute rejection of pig 
xenografts. The anti-non gal Ab barrier still presents a challenge that requires the 
development of novel immunological treatments which prevent the production of these 
Abs. It is possible that without overcoming the anti-non gal Ab barrier it may be difficult to 
progress in clinical xenotransplantation beyond the use of short term bridge xenografts. 
Both the anti-Gal and anti-non gal barriers have been the focus of many studies in 
nonprimate mammal and in monkeys. This chapter does not intend to review the vast 
literature on anti-Gal and anti-non gal immune response in experimental animal models, but 
aims primarily to describe the information gained in studying anti-Gal and anti-non gal Ab 
response in humans. Although xenotransplantation is rarely performed in humans, I have 
had the opportunity of collaborating with several groups that introduced xenogeneic cells or 
tissues expressing -gal epitopes into humans and study anti-Gal and anti-non gal Ab 
response in the sera of such patients. I believe that the information gained in these studies 
may contribute to the understanding of the immune response to -gal epitopes and to 
xenoantigens that induce the anti-non gal Ab response in humans. 
2. The anti-Gal Ab and the -gal epitope 
Anti-Gal is the most abundant Ab in humans, comprising ~1% of circulating 
immunoglobulins (Galili et al., 1984). This Ab is present in the serum as IgG, IgM and IgA 
isotypes and in various body secretions as IgG and IgA (Galili et al., 1984; Hamadeh et al., 
1995; Yu et al., 1999). In recent studies, anti-Gal was found in some individuals also as an 
IgE Ab that can mediate a systemic allergic reaction following the infusion of the 
monoclonal Ab cetuximab which carries -gal epitopes on its Fab (Chung et al. 2008). The 
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isotype switch into anti-Gal IgE was reported to be associated with biting of the tick 
Amblyomma americanum which transmits lime disease (Commins et al., 2011). Although anti-
Gal is present in large amounts in humans it interacts with a very high specificity with a 
carbohydrate antigen (Ag) called the -gal epitope (Gal1-3Gal1-4GlcNAc-R) on 
glycolipids and glycoproteins (Galili et al., 1985; 1987a). Anti-Gal is produced in humans 
throughout life as a result of continuous antigenic stimulation by gastrointestinal bacteria 
with cell wall carbohydrate Ags that have a structure similar to the -gal epitope (Galili et 
al. 1988a). Anti-blood group A and B Abs are also produced as a result of antigenic 
stimulation by the gastrointestinal flora (Springer & Horton, 1969). However, anti-Gal 
differs from these blood group Abs in that it is produced in all humans who are not severely 
immunocompromized. In individuals with blood type A and O, >80% of anti-blood group B 
activity is in fact by anti-Gal Abs that are capable of binding to -gal epitopes despite of the 
branching fucose, as in blood group B Ag (i.e. Gal1-3(Fuc1-2)Gal1-4GlcNAc-R) (Galili et 
al., 1987a; McMorrow et al., 1997). However, in blood group B and AB individuals, anti-Gal 
exclusively interacts with the -gal epitope and not with other carbohydrate structures. 
In contrast to protein Ags, carbohydrate Ags (with the exception of sialic acid) have no 
electrostatic charges. Therefore the affinity of anti-Gal to the -gal epitope is much lower 
than that of anti-protein Abs. Affinity analysis performed by equilibrium dialysis using free 
-gal epitope as the radiolabeled trisaccharide [3H]Gal1-3Gal1-4GlcNAc have indicated 
that the affinity is highly variable in different individuals and it ranges between 2x105 to 
6x106M-1 (Galili & Matta, 1996). However, since anti-Gal is produced in very large amounts, 
it is very effective in inducing destruction of pig cells and tissues expressing -gal epitopes 
on their surface (Galili, 1993; Good et al., 1992; Sandrin et al., 1993; Collins et al., 1994). 
The proportion of B cells capable of producing anti-Gal is ~1% of circulating B cells, whereas 
the proportion of B cells capable of producing anti-blood group A or B Abs is 4-5 fold lower 
(Galili et al., 1992). This could be determined by immortalization of human blood B cells by 
Epstein Barr virus and the growth of such cells as individual clones. One in 100 B cells 
produces anti-Gal in vitro whereas only one in 400-500 B cell clones produces anti-blood 
group A or B Abs (Galili et al., 1993). Most of B cells capable of producing the anti-Gal Ab 
(designated anti-Gal B cells) are quiescent and only those along the gastrointestinal tract 
continuously produce this natural Ab. Analysis of the immunoglobulin genes in anti-Gal B 
cells indicated that this is a polyclonal population, however, the immunoglobulin heavy 
chain genes in most clones, cluster in the VH3 family (Wang et al., 1995). 
3. Distribution of the -gal epitope and anti-Gal Ab in mammals 
The -gal epitope is unique to mammals, where it is found as 1x106-30x106 epitopes/cell and is 
completely absent in fish, amphibians, reptiles, or birds (Galili et al., 1987b, 1988b).  Among 
mammals, -gal epitopes are present on cells of marsupials such as kangaroo and opossum 
and on cells of  non-primate placental mammals like mouse, rat, rabbit, bat, pig, cow, horse, 
cat, dog, and dolphin (Galili et al. 1987b, 1988b). The -gal epitope is also found in similar 
abundance on cells of prosimians (e.g., lemurs), and New World monkeys (i.e., monkeys of 
South America), but not on cells of Old World monkeys (monkeys of Asia and Africa), apes 
(e.g., chimpanzee, gorilla and orangutan), and humans (Galili et al., 1987b, 1988b).  In contrast, 
humans, apes and Old World monkeys are not immunotolerant to the -gal epitope and they 
all produce large amounts of the natural anti-Gal Ab against it (Galili et al., 1987b). 
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The unique distribution of -gal epitopes and the anti-Gal Ab in mammals is the result of 
the differential activity of the glycosylation enzyme 1,3galactosyltransferase (1,3GT) 
which is active in the trans-Golgi compartment where it transfers galactose from the sugar 
donor UDP-Gal to N-acetyllactosamine (Gal1-4GlcNAc-R) on carbohydrate chains of 
glycoproteins and glycolipids to synthesize the -gal epitope. The 1,3GT gene (also 
referred to as Ggta1) is expressed in mammalian cells but is inactive in humans, apes and 
Old World monkeys (Galili et al. 1988b; Thall et al. 1991). This inactivation is primarily the 
result of various deletions in the Ggta1 gene causing frame shift mutations in the open 
reading frame and the generation of pre-mature stop codons (Larsen et al., 1990; Joziasse et 
al., 1992; Galili & Swanson, 1992; Koike et al., 2002). Studies evaluating the expression of this 
pseudo-gene in humans by PCR have demonstrated its low transcription (Koike et al., 2002), 
however, since the protein molecule is truncated, it is devoid of catalytic activity. Truncation 
studies in the New World monkey 1,3GT have indicated that deletion of as few as three 
amino acids at the C-terminus is sufficient to result in complete lose of catalytic activity 
(Henion et al., 1994). Comparison of the sequence of this pseudogene in humans and in 
other primates led us to suggest that the 1,3GT gene was inactivated in ancestral Old 
World primates, after apes and monkeys diverged from each other, 20-25 million years ago 
(Galili & Swanson, 1992; Galili & Andrews, 1995). 
4. The rejection of xenografts by the anti-Gal Ab 
Several seminal studies demonstrated in vitro the destruction of cells by complement 
mediated cytolysis (Good et al., 1992, Sandrin et al., 1993) or by Ab dependent cell mediated 
cytotoxicity (ADCC) (Galili, 1993; Watier et al., 1996) due to interaction of human anti-Gal 
Ab with -gal epitopes on pig cells or on monkey cells transfected with 1,3GT gene and 
thus expressing the -gal epitopes on their cell membrane.  In in vivo studies, 
transplantation of pig or New World monkey xenografts into Old World monkeys was 
found to result in in situ binding of anti-Gal to -gal epitopes on endothelial cells of grafts, 
complement mediated lysis of these cells due to this Ag/Ab interaction, the ensuing 
collapse of the vascular bed and hyper acute rejection of the xenograft (Collins et al., 1994).  
Subsequent studies demonstrated the direct association between in vivo neutralization of 
anti-Gal by -gal oligosaccharides and delay in hyperacute rejection (Simon et al., 1998), and 
the association between removal of anti-Gal by adsorption on affinity columns and delay in 
xenograft rejection (Kozlowski et al., 1998; Xu et al., 1998). These studies directly proved that 
the anti-Gal Ab is the Ab mediating hyperacute rejection of xenogafts  in vivo.  
5. Stimulation of the immune system to produce anti-Gal Ab in xenograft 
recipients 
Anti-Gal is present in very high amounts in all individuals who are not severely 
immunocompromized. Nevertheless, the human immune system is capable of producing 
this Ab in much higher titers due to the activation of many of the quiescent anti-Gal B cells 
throughout the body. As indicated above, ~1% of B cells in the blood have the capacity of 
producing the anti-Gal Ab, but are in a quiescent state (Galili et al., 1993). However, in 
individuals who are transplanted with xenografts that present -gal epitopes, these 
quiescent B cells are readily activated to produce the anti-Gal Ab. The activated anti-Gal B 
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cells further undergo isotype switch as well as affinity maturation, ultimately resulting in an 
increase of ~100 fold in the titer of this Ab.   
Anti-Gal Ab response to -gal epitopes on xenogeneic cells could be monitored in an 
ovarian carcinoma patient who received an experimental gene therapy treatment for 
destruction of tumor cells by ganciclovir (Galili et al., 2001). The patient received 3 
intraperitoneal infusions in 7 weeks intervals, each of 6x109 mouse fibroblasts that released a 
replication defective retro-virus containing the thymidine kinase gene. Tumor cells infected 
in situ by the virus are killed by subsequent administration of ganciclovir (Link et al., 1996).  
Since the infused mouse fibroblasts present multiple -gal epitopes (Galili et al., 1988b), this 
treatment is immunologically similar to the transplantation of xenograft cells expressing -
gal epitopes in humans. Anti-Gal activity in the serum of the patient was studied by ELISA 
with synthetic -gal epitopes linked to bovine serum albumin (-gal BSA) as solid phase Ag.  
Within one week post infusion of mouse fibroblasts, the titer of anti-Gal IgG Ab increased 
by ~10 fold, and two weeks post post infusion by ~100 fold (Galili et al., 2001) (Fig. 1). The 
Ab activity remained at that high level after the second and third infusions. This extensive 
anti-Gal Ab response was the result of activation of the many anti-Gal B cell clones that 
engage -gal epitopes on the glycoproteins released from the infused mouse fibroblasts. 
Studies measuring the concentration of anti-Gal in the serum (by isolation on an -gal 
column) and its affinity (by dialysis of radiolabled free -gal epitope in the form of 
trisaccharide [Galili & Matta, 1996]) indicated that the 10 fold increase in anti-Gal titer 
within the first week post transplantation was the result of an increase in the concentration 
of anti-Gal Ab in the serum (i.e. increased production of the Ab), whereas the additional 10 
fold increase within the second week was associated with a corresponding increase in the 
affinity of this Ab (Galili et al., 2001). These findings strongly suggest that the increase in the 
titer of anti-Gal Ab observed after one week is the result of activation of quiescent anti-Gal B 
cells by -gal epitopes on glycoproteins released from the xenograft cells, thereby increasing 
the concentration of this Ab in the serum. The subsequent increase in affinity of the Ab 
observed at the end of the second week is probably a result of affinity maturation by the 
process of somatic mutations within anti-Gal B cell clones. This process occurs after the 
initial activation of the quiescent anti-Gal B cells.  
The increase in anti-Gal Ab response was mostly (~90%) of the IgG2 subclass and the 
remaining was of the IgG3 subclass. No significant increase was observed in the activity of 
anti-Gal IgG1, IgG4, IgM or IgA (Galili et al., 2001). This suggests that the isotype switch of 
anti-Gal B cells stimulated by -gal presenting xenoglycoproteins (-gal glycoproteins) is 
quite rapid from IgM to IgG2 and IgG3. It should be stressed, however, that anti-Gal IgM is 
naturally present in large amounts in human serum (Hamadeh et al., 1995; Yu et al., 1999) 
and anti-Gal IgA and IgG are present in various secretion such as saliva, milk, colostrum 
and bile (Hamadeh et al., 1995). 
Activation of anti-Gal B cells and production of the anti-Gal Ab by plasma cells seems to 
occur as long as there are glycoproteins with -gal epitopes in the body. The decrease in 
anti-Gal titer observed 4 and 7 weeks after the first infusion of mouse fibroblasts (Fig. 1) 
suggests that after the anti-Gal mediated destruction of these cells and the elimination of -
gal glycoproteins, anti-Gal B cells cease to be activated and to differentiate into plasma cells 
secreting the Ab. Since the period of Ab secretion by plasma cells is limited, activity of anti-
Gal Ab decreases in the serum within a short period after the elimination of glycoproteins 
www.intechopen.com
 
Anti-Gal and Anti-Non Gal Antibody Barriers in Xenotransplantation 
 
7 
with -gal epitopes.  It is of interest to note that anti-Gal production after the second and 
third infusions of mouse fibroblasts was not higher than that observed after the first infusion 
(Fig. 1). It is probable that high affinity anti-Gal IgG molecules produced in large amounts, 
effectively mask -gal epitopes on glycoproteins released from the infused cells. Such 
masking limits the extent of further B cell activation and keeps that activation at a level of 
Ab production similar to that observed 2 weeks after the first infusion.     
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Fig. 1. Production of anti-Gal (open columns) and anti-non gal IgG Abs (closed columns) in 
an ovarian carcinoma recipient of 6x109 mouse fibroblasts. The patient received 3 
intraperitoneal infusions of the fibroblasts in 7 week intervals. Ab titers were determined 
prior to treatment, 1, 2, 4 and 7 weeks post treatment, 2 weeks after the second (2nd) and 
third (3rd) treatments. The titers are presented as reciprocals of serum dilution yielding half 
the maximum binding in ELISA. The solid phase Ags used for the study were synthetic -
gal epitopes linked to BSA (-gal BSA) for anti-Gal Ab analysis and the mouse fibroblast cell 
line used in the treatment for anti-non gal Ab analysis. Sera were depleted of anti-Gal Ab 
prior to performing the assay for anti-non gal Abs (modified from Galili et al., 2001). 
A similar extensive increase in anti-Gal titer was observed in patients with impaired liver 
function, who were treated by temporary extracorporeal perfusion of their blood through a 
pig liver (Cotterell et al., 1995; Yu et al. 1999). The increase in anti-Gal titer in these patients 
implies that the release of xenoglycoproteins from the pig liver, perfused for several hours, 
was sufficient to induce the activation of the many quiescent anti-Gal B cells for production 
of the anti-Gal Ab. Interestingly, a similar rapid and extensive increase in anti-Gal IgG 
activity was observed in cynomolgus monkeys (an Old World monkey) implanted with pig 
meniscus cartilage which contains an abundance of -gal epitopes (Galili et al., 1997). This 
suggests that non-human primates capable of producing anti-Gal Ab also have multiple 
quiescent anti-Gal B cells as those in humans.    
6. Anti-Gal Ab production in immunosuppressed xenograft recipients 
The extensive activation of anti-Gal B cells by -gal epitopes on xenografts is very difficult 
to suppress. This can be inferred from the studies on anti-Gal response in diabetic patients 
who were transplanted by Groth and colleagues with an allogeneic kidney together with pig 
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fetal islet cell clusters (Groth et al., 1994; Galili et al., 1995). These studies were the first to 
demonstrate the induced anti-Gal Ab response in xenograft recipients. Pig islet cell clusters 
were generated by culturing of fetal pig pancreatic tissues (Korsgren et al. 1988). The fetal 
islet cells proliferate in vitro and form clusters of islet cells which were transplanted at a 
volume corresponding to 2-6 ml packed cells (Groth et al., 1994). The islet cell clusters were 
implanted under the transplanted kidney capsule or infused into the portal vein in the liver.  
Recipients of the kidney allograft and the islet cell xenografts displayed an increase of 20-80 
folds in anti-Gal titer within the period of 25-50 days post transplantation (Galili et al., 1995). 
As with the ovarian carcinoma patient infused intraperitoneal with the mouse fibroblasts 
(Galili et al., 2001), the increase in anti-Gal activity was mostly in the IgG isotype and to a 
much lesser extent of IgM and IgA isotypes. However, unlike the ovarian carcinoma patient, 
the transplanted diabetic patients were heavily immunosuppressed, to the extent that the 
immune system did not reject the kidney allograft (Groth et al., 1994). The increased 
production of anti-Gal Ab in these immunosuppressed patients suggests that currently used 
immunosuppressive protocols, which are effective enough to prevent allograft rejection, fail 
in preventing much of the activation of anti-Gal B cells by -gal glycoproteins released from 
the xenograft.   
Studies in 1,3galactosyltransferase knockout mice that are capable of producing anti-Gal 
Ab have indicated that stimulation of anti-Gal B cells by -gal epitopes on xenografts to 
produce the anti-Gal Ab requires T cell help. However, the -gal epitope by itself (like other 
carbohydrate chains of the complex type) can not activate helper T cells (Tanemura et al., 
2000).  T cell help for anti-Gal B cells is provides by helper T cells activated by the multiple 
xenogeneic peptides processed and presented by antigen presenting cells (Tanemura et al., 
2000; Galili 2004). Interestingly, in the absence of T cell help, interaction between -gal 
epitopes and B cell receptors on anti-Gal B cells results in induction of immune tolerance to 
-gal epitopes and prevention of anti-Gal Ab production in the tolerized recipients 
(Mohiuddin et al., 2003; Ogawa et al., 2003). A similar tolerance induction was achieved by 
bone marrow chimerism with -gal epitope presenting syngeneic bone marrow cells (Bracy 
et al., 1998). 
7. Elimination of the anti-Gal Ab barrier by the use of 
1,3galactosyltransferase knockout pigs  
As indicated above, the natural anti-Gal Ab and the elicited anti-Gal Ab are of no clinic 
significance in xenograft recipients, if the xenograft is obtained from 
1,3galactosyltransferase knockout pigs. These pigs have been generated by targeted 
disruption (knockout) of the 1,3galactosyltransferase gene (Phelps et al., 2003; Kobler-
Simond et al., 2004; Yamada et al., 2005; Takahagi et al., 2005; McGregor et al., 2011). These 
pigs lack -gal epitopes and their organs do not induce an anti-Gal response when 
transplanted into primates (Chen et al., 2005; Ezzelarab et al., 2006; Hisashi et al., 2008; Yeh 
et al., 2010). Thus, in contrast to rapid (hyperacute) rejection of wild type (WT) pig organs in 
monkeys (observed within <1h to several hours), pig organs from 1,3galactosyltransferase 
knockout pigs (1,3GT KO pigs) survive in monkeys for weeks to several months prior to 
rejection (Yamada et al., 2005; Chen et al., 2005;  Kuwaki et al., 2005; Tseng et al., 2005; 
Hisashi et al., 2008). In the absence of anti-Gal response the next immune obstacle in 
xenotransplantation became apparent- the production of anti-non gal Abs against 
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xenoantigens of the graft which are not -gal epitopes. Most of these xenoantigens are 
multiple pig proteins that are immunogenic in humans.  
8. Most of the proteins within pig xenografts are expected to be immunogenic 
in humans 
The amino acid sequence of most homologous (orthologous) proteins varies in different 
mammals. There are only few highly conserved proteins, such as histones and collagen in 
which amino acid sequence changes have been minimal because of functional constraints. 
However, most genes accumulate random mutations (referred to as the evolutionary 
molecular clock [Wilson & Sarich, 1969]) which result in variations in amino acid sequence. 
Since humans and pigs (as well as other nonprimate mammals) have been evolving 
independently along separate lineages for an evolutionary period estimated to be ~75 
million years (Pilbeam 1984), each has accumulated multiple lineage and species specific 
mutations. The proportion of such mutations varies in different regions of a given protein, 
based on functional constraints, e.g. in a membrane bound receptor there are more 
mutations in the tether region than the ligand binding region. Regardless of their location, 
mutations form immunogenic amino acid sequences in pig proteins, since they are absent in 
humans. The immune system can react against very small changes in various Ags. This can 
be inferred from the immune response to blood group Ags where the presence of one small 
N-acetyl group (CH3CONH) in blood group A and its absence in blood group B is sufficient 
for inducing production of anti-A Abs in blood group B individuals. Because most pig 
proteins contain some amino acid sequences that are different from those in homologous 
proteins in humans, it is likely that most pig proteins are immunogenic in humans and can 
induce an Ab response in xenograft recipients. Therefore, humans transplanted with pig 
cells or organs may produce hundreds and possibly thousands of Ab specificities against 
pig xenogeneic peptides. These Abs have been referred to as anti-non gal Abs (Galili et al., 
2001). Since there are very large numbers of undefined xenoantigens that elicit anti-non gal 
Ab response, pig tissues or cells may serve as antigenic preparations for analysis of such 
Abs. For such analysis, anti-Gal Abs have to be removed from the tested human sera prior to 
the assay. This anti-Gal depletion is feasible by adsorption of anti-Gal Ab on rabbit RBC or 
on glutaraldehyde rabbit RBC (Galili et al., 2001; Stone et al., 2007) since these RBC present 
the highest number of -gal epitopes among mammalian RBC (Ogawa & Galili, 2006). As 
described below, studies on anti-non gal Abs in xenograft recipients have indicated that 
their production is very different from that of elicited anti-Gal Abs.  
9. Anti-non gal Abs in a recipient of mouse fibroblasts 
The studies on the Ab response in the ovarian carcinoma patient receiving intraperitoneal 
infusion of mouse fibroblasts led to the first report on production of anti-non gal Abs in 
humans that are recipients of a xenograft (Galili et al. 2001). Although, in this patient the 
anti-non gal Ab response was against mouse proteins, the results of this analysis are also 
applicable to the understanding of anti-non gal immune response to pig proteins. This is 
since the evolutionary distance between humans and rodents does not differ significantly 
from the distance between humans and pigs (i.e. ~75 million years of evolution in separate 
lineages since the “great mammalian radiation”) [Pilbeam 1984]. Anti-non gal Ab activity in 
that patient could be determined by ELISA with the mouse fibroblast cell line used in the 
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treatment, as a solid phase Ag. These fibroblasts strongly adhere to ELISA wells following 
the overnight drying of the cell suspension in the wells. Serum samples from various time 
points post intraperitoneal infusion were the same as those used for anti-Gal analysis (Fig. 
1), however, the sera were depleted of anti-Gal Abs by adsorption on rabbit RBC (50%) on 
ice (Galili et al., 2001).  
Although anti-Gal IgG Ab activity increased by ~14 days post administration of the mouse 
fibroblasts, no induced anti-non gal Ab production was detected at that time point (Fig. 1). 
These Abs were not detected even 7 weeks after the first infusion. However, within 2 weeks 
after the second infusion, a robust anti-non gal Ab response was observed in the serum of 
the patient (Fig. 1). Western blot analysis indicated that the Abs produced bound to multiple 
proteins in the mouse fibroblasts, confirming the multiclonality of the B cell response (Galili 
et al. 2001). It is probable that there are also many T cell clones that are activated by 
xenogeneic peptides processed and presented by the antigen presenting cells of the treated 
patient. Nevertheless, the lack of detectable induced anti-non gal Ab response after the first 
fibroblast infusion strongly supports the assumption that the initial number of anti-non gal 
B cells in each of the multiple B cell clones reacting against xenoantigens is very low. By the 
time B cells in these multiple clones proliferate to the extent required for producing 
detectable levels of anti-non gal Abs, the stimulatory fibroblasts have disappeared due to 
anti-Gal Ab mediated destruction. Thus, production of anti-non gal Abs is detectable only 
after the second infusion of mouse fibroblasts which provides an antigenic boost for the 
activation of anti-non gal memory B cells. As shown below, anti-non gal Abs appear at 
earlier time point in recipients of pig tissue (tendon) because of the continuous antigenic 
stimulation by the pig xenoantigens. The subclass distribution of the induced anti-non gal 
Abs was found to be IgG1>IgG2>IgG3>IgG4 (Galili et al. 2001).  
It is of interest to note that the titer of anti-non gal Abs measured after the third infusion 
(performed 7 weeks post second infusion) did not differ from that after the second infusion 
(Fig. 1). These observations strongly suggests that, as with anti-Gal Ab response, anti-non 
gal Ab response is subjected to a self limiting dynamic regulatory mechanism. This self 
limiting production of anti-non gal Abs may be mediated by such Ab molecules that bind to 
the immunogenic peptide epitopes and mask them, thereby preventing additional 
stimulation of the corresponding B cells.  
10. Anti-non gal Ab response in recipients of pig ligament 
A phase I clinical trial on replacement of torn anterior cruciate ligament (ACL) with pig 
patellar tendon provided a unique opportunity for monitoring anti-non gal Ab response in the 
absence of immunosuppression in humans, for a period of 2 years (Stone et al. 2007). The 
implanted ligaments and the two attached bone blocks were treated with recombinant -
galactosidase in order to eliminate -gal epitopes. This enzymatic treatment was performed in 
order to attenuate the immune response to the implant by preventing the induction of anti-Gal 
Ab response which can be detrimental to the implant. In addition, the ligaments underwent 
mild cross-linking by incubation for 12 hours with 0.1% glutaraldehyde. It was assumed that 
in the absence of anti-Gal response, destruction of the pig ligament mediated by anti-non gal 
Abs will be slowed due to the cross-linking. The slowed destruction of the cross-linked 
ligament will enable concomitant regeneration of the ligament tissue (ligamentization) by 
infiltrating fibroblasts which align with the pig collagen fiber scaffold and produce new 
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collagen fibers. It was further assumed that the similarity in the rates of pig ligament 
destruction and ligamentization by human fibroblasts will maintain the biomechanical 
characteristics of the implanted ligament while it is gradually replaced by the human tissue. 
Five patients receiving such implants 9-10 years ago continue to display normal joint activity. 
Anti-non gal Ab response was studied in implanted patients by ELISA with pig ligament 
homogenate as solid phase Ag, using sera that were depleted of anti-Gal Ab. Induction of anti-
non gal Ab production was determined by comparison of the post-implantation Ab activity at 
various serum dilutions with that in the pre-implantation base-line activity. The induced anti-
non gal Ab response peaked 2 - 6 months post implantation (Fig. 2) (Stone et al. 2007). This Ab 
response was detectable also after 1 year, but it returned to the pre-implantation level after 2 
years. These observations suggest that as long as the pig tissue is present within the recipient, 
the immune system is stimulated to produce anti-non gal Abs. However, due to the gradual 
replacement with human ligament tissue, the amount of pig ligament tissue is decreasing, so 
that by 12 months anti-non gal Ab response is lower than in the peak of 2-6 months. By 24 
months, the pig ligament seems to be completely replaced by human ligament tissue therefore 
there is no antigenic stimulation for the production of anti-non gal Abs. 
Anti-non gal IgG Ab activity in the pig ligament recipients increased on average by 5-10 
folds in comparison with pre-implantation serum in each of the patients (Stone et al., 2007). 
This increase is much lower than the ~100 fold increase in anti-Gal Ab activity observed in 
the patient receiving intraperitoneal infusion of mouse fibroblasts. The difference is likely to 
be due to the much higher number of quiescent anti-Gal B cells (~1% of B cells [Galili et al., 
1993]) which are rapidly activated by -gal epitopes on xenoglycoproteins. The ultimate 
number of anti-non gal B cells at the peak of the immune response is likely to be much lower 
in each of the individual clones, thus, the overall immune response is significantly lower 
than that of the anti-Gal response.  
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Fig. 2. Anti-non gal Ab (IgG) activity in the sera of 3 patients implanted with pig patellar 
tendon for replacement of torn ACL. The pig tendons were treated with -galactosidase for 
destruction of -gal epitopes and cross-linked mildly with glutaraldehyde prior to 
implantation. Ab activity was determined by ELISA with pig ligament homogenate as solid 
phase Ag. Sera were depleted of anti-Gal Ab prior to analysis. Ab binding was determined 
at serum dilution of 1:640 and presented as O.D. (optical density units) at the various time 
points (modified from Stone et al., 2007).   
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The specificity of the anti-non gal Abs could be studied by Western blots. Pre-implantation 
sera depleted of anti-Gal Abs displayed no Ab binding to pig ligament proteins or to pig 
kidney proteins. However, sera obtained 6 months post implantation contained anti-non gal 
Abs that bound to multiple pig ligament proteins. This large number of Ab specificities was 
indicated by the immunostaining of the blot as a smear rather than as individual bands 
(Stone et al., 2007). Many of stained proteins were also found in pig kidney preparations, 
implying that some of the proteins inducing anti-non gal Ab response are not specific to the 
ligament and are present in other tissues, as well. Blots of human ligament proteins were 
also studied for binding of anti-non gal IgG Abs. Despite the extensive binding of Abs to pig 
ligament proteins, no binding was observed with human ligament proteins. This strongly 
suggests that exposure of the human immune system to pig proteins and the extensive 
production of Abs against such proteins does not result in breakdown of immune tolerance 
to self Ags and no auto-Abs are generated.  
It is not clear as yet whether the anti-non gal Ab response also includes Abs to carbohydrate 
Ags other than the -gal epitope. A number of studies demonstrated the production of 
natural Abs to N-glycolylneuraminic acid in humans and the presence this epitope on pig 
cells (Zhu & Hurst, 2002; Miwa et al., 2004; Taylor et al., 2010). However, analysis of sera 
from monkeys sensitized to 1,3GT KO pig tissue demonstrated no significant elevation in 
the activity of such Abs (Yeh et al., 2010).  
11. Anti-non gal Ab response in immunosuppressed recipients 
The study of sera in diabetic recipients of pig fetal islet cell clusters enabled the assessment of 
anti-non gal Ab production in recipients of pig fetal islet cell xenograft and of a kidney 
allograft. These recipients were immunosuppressed to the extent that they did not reject the 
allograft (Groth et al., 1994). As indicated above, the immunosuppressive treatment in these 
patients did not prevent the induced anti-Gal immune response against -gal epitopes on 
xenoglycoproteins. In order to estimate the proportion of anti-Gal and anti-non gal Abs of the 
total Ab binding to pig cells, binding of IgG Abs to pig PK15 kidney cells was measured in 
serum of transplanted patients and compared to the binding of Abs after anti-Gal depletion by 
binding of the Ab to -gal epitopes linked to silica beads. Ab binding to pig cells in serum 
depleted of anti-Gal was 6-25% of the total IgG binding (Galili et al., 1995). These findings 
suggest that anti-Gal response comprised the majority of the human immune response to pig 
xenograft. Nevertheless, a significant proportion of the Abs was anti-non gal Abs produced 
despite immunosuppression effective enough to prevent the rejection of the kidney allograft.  
Anti-non gal Ab production in the immunosuppressed recipients of kidney allograft and pig 
islet cell xenografts raises the question of whether these Abs are potent enough to mediate 
rejection of the xenograft.  There is no direct information to address this question. Studies of 
xenotransplantation under immunosuppression of wild type pig heart and kidney into 
monkeys demonstrated anti-non gal Ab production, even if the xenograft was rejected within 
few days (Buhler et al., 2003; Lam et al., 2004; Chen et al., 2005; Ezzelarab et al., 2006). 
Transplantation of 1,3GT KO pig heart or kidney in monkeys subjected to a variety of 
immunosuppressive protocols resulted in survival of the xenografts for  much longer periods 
(from several days up to 3 months [even up to 6 months in one recipient of heart xenograft]) 
than survival of xenografts from wild type pigs presenting multiple -gal epitopes (Kuwaki et 
al., 2005; Chen et al., 2005; Tseng et al., 2005; Chen et al., 2006;  Ezzelarab et al., 2006; Hisashi et 
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al., 2008). Ultimately, all xenografts were rejected and the recipient monkeys were found to 
produce anti-non gal Abs which could be detected in vitro as Abs binding to 1,3GT KO pig 
cells. Although not directly proven, it is probable that these anti-non gal Abs contribute 
significantly to the observed rejection of 1,3GT KO pig xenografts.  
12. Challenges in preventing anti-non gal Ab response in xenograft recipients 
The prevention of anti-non gal Ab response in a xenograft recipient is a formidable 
challenge. As discussed above, this Ab response is the result of activation of multiple B cell 
clones against a very large number of immunogenic peptides on many pig proteins. It is 
probable that the multiple immunogenic peptides processed and presented by antigen 
presenting cells activate a very large number of helper T cell clones that facilitate anti-non 
gal Ab response. The studies mentioned above, which have demonstrated anti-non gal Ab 
response in immunosuppressed pig xenograft recipient monkeys imply that the 
immunosuppression protocols presently used for preventing allograft rejection do not 
completely prevent anti-non gal Ab response. Thus, a major challenge in 
xenotransplantation is the development of immunosuppressive drugs and protocols that 
prevent anti-non gal immune response but do not completely eliminate the ability of the 
immune system to protect against microbial pathogens. It is not clear at present whether 
such a selective immune suppression against multiple xenoantigens but not against 
microbial Ags is feasible. An alternative approach for preventing anti-non gal Ab response 
may be the induction of immune tolerance to the multiple pig xenoantigens. One method 
studied for inducing such a tolerance in kidney xenograft recipients has been the thymo-
kidney xenograft of 1,3GT KO pigs (Yamada et al., 2005). Pig thymus tissue is placed under 
the pig kidney capsule several weeks prior to transplantation in order to achieve 
vascularization of this tissue. The thymus component of the xenograft is expected to tolerize 
the recipient against pig xenoantigens (Yamada et al., 2005). Pig thymo-kidney xenografts 
that were transplanted into monkey recipients survived for almost 3 months, a much longer 
period than the survival period of kidney xenografts lacking the thymus component 
(Yamada et al., 2005; Griesemer et al., 2009). 
It may be possible that xenograft recipients will ultimately have to be tolerized to pig 
xenoantigens by manipulating their immune system prior to the xenotransplantation 
procedure. One theoretical possibility may be the effective pre-transplantation elimination 
of B cells of the patients. Newly emerging B cell clones with anti-pig Ag specificity that 
develop in the presence of the xenograft Ags (i.e. post transplantation) may be deleted from 
the repertoire at the differentiation stage of immature B cells in which B cells engaging Ags 
are eliminated or undergo receptor editing (Sandel & Monroe 1999; Nemazee et al., 2000). It 
is not known at present whether elimination of these B cells will suffice for preventing 
rejection, or is T cell elimination required as well. An additional tolerance induction method 
that is being explored is the administration of pig bone marrow cells in order to induce bone 
marrow chimerism which may prevent an immune response to pig xenoantigens. 1,3GT 
KO pig bone marrow cells were reported to survive in two out of four monkeys for at least 4 
weeks (Griesemer et al., 2010). It is not known as yet whether such chimerism can be 
maintained for much longer periods and if it can prevent anti-non gal Ab response. In 
addition, it is not clear whether such chimerism can tolerize against xenoantigens that are 
not present on bone marrow cells (e.g. Ags specific to the pig xenograft organ). All these 
considerations imply that although the anti-Gal barrier has been effectively overcome, much 
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research is still required for developing methods to overcome the anti-non gal immune 
response against the wide range of pig xenoantigens that are immunogenic in humans.  
13. Concluding remarks 
Two types of Abs form immune barriers in xenotransplantation: anti-Gal and anti-non gal 
Abs. The anti-Gal Ab is naturally present in humans in large amounts. The titer of anti-Gal 
Ab further increases in xenograft recipients by 30-100 fold because of the rapid activation of 
quiescent anti-Gal B cells which comprise ~1% of circulating B cells in humans. Production 
of anti-non gal Abs in xenograft recipients is the result of the immune response against the 
multiple pig proteins that are immunogenic in humans because of mutations in orthologous 
pig proteins. Anti-non gal Abs are produced by a large number of B cell clones with Ab 
specificity to the many pig peptide sequences that are not present in humans. Both anti-Gal 
and anti-non gal Abs are produced in humans despite immune suppression that is effective 
enough in preventing allograft rejection. Anti-Gal and anti-non gal Abs are continuously 
produced as long as the corresponding Ags are present in the treated patient. The 
generation of 1,3galactosyltransferase knockout pigs enabled the elimination of anti-Gal 
barrier in xenotransplantation since these pigs lack -gal epitopes. However, overcoming 
the anti-non gal Ab barrier requires the development of novel methods that selectively 
prevent the induced production of these Abs while maintaining protective immune 
response against various pathogens.  
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allotransplantation resumed the interest of xenotransplantation, especially porcine islet transplantation and
some exceptions. Clinical trials were done in many countries so far, such as Sweden, China, Mexico, USA
(Inventory of Human Xenotransplantation Practices - IXA and HUG in collaboration with WHO). In addition, a
new clinical trial was approved by the government, and resumed the porcine islet transplantation research in
New Zealand two years ago.
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